RECRUITING

A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)

Talk to us

Conditions

Colorectal CancerPharmacologicColectomy specimens22-254

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study will collect biospecimens (including blood, tissue, and stool samples) and health information to create a database-a type of collection of information-for better understanding young onset colorectal cancer (YOCRC). The study will include both people with YOCRC and healthy people.

Official Title

Investigation of the Potential Effects of Pharmacologic Agents on Young Onset- Colorectal Cancer

Quick Facts

Study Start:2022-09-30
Study Completion:2025-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05568420

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 49 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * 18-49 years old
  2. * Histological or cytological diagnosis of colorectal adenocarcinoma
  3. * Planned CRC resection biopsy, or colonoscopy ,including surveillance colonoscopies and/or have already undergone prior surgical resection, with tissue, including normal colonic mucosae distant from the malignant tumor (only patients providing tissue sample)
  4. * Enrollment in IRB# 20-315, Young Onset Gastrointestinal Cancer Prospective Registry (Andrea Cercek, PI)
  5. * 18-49 years old at time of diagnosis
  6. * Scheduled for standard-of-care colonoscopy at MSK
  1. * CRC Cohort:
  2. * Antibiotic use within 6 months of collection of stool for gut microbiome analysis s (only patients providing stool sample)
  3. * Known inherited cancer susceptibility gene
  4. * History of inflammatory bowel disease
  5. * Antibiotic use within 6 months of collection of stool for gut microbiome analysis (only patients providing stool sample)
  6. * History of or prior treatment for cancer ≤ 5 years prior to registration. Exceptions include non-melanoma skin cancer, ductal carcinoma in situ, bladder carcinoma in situ, or carcinoma-in-situ of the cervix.
  7. * Colonoscopy for indications of IBD, anemia and/or genetic predisposition (only patients providing tissue sample).

Contacts and Locations

Study Contact

Andrea Cercek, MD
CONTACT
646-888-4189
cerceka@mskcc.org
David Kelsen, MD
CONTACT
646-888-4179

Principal Investigator

Andrea Cercek, MD
PRINCIPAL_INVESTIGATOR
Memorial Sloan Kettering Cancer Center

Study Locations (Sites)

Memorial Sloan Kettering Cancer Center
New York, New York, 10065
United States

Collaborators and Investigators

Sponsor: Memorial Sloan Kettering Cancer Center

  • Andrea Cercek, MD, PRINCIPAL_INVESTIGATOR, Memorial Sloan Kettering Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-09-30
Study Completion Date2025-09

Study Record Updates

Study Start Date2022-09-30
Study Completion Date2025-09

Terms related to this study

Keywords Provided by Researchers

  • Pharmacologic
  • Colectomy specimens
  • 22-254

Additional Relevant MeSH Terms

  • Colorectal Cancer